PMID- 27736006
OWN - NLM
STAT- MEDLINE
DCOM- 20170503
LR  - 20170503
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 46
IP  - 12
DP  - 2016 Dec
TI  - Body mass index and response to abatacept in rheumatoid arthritis.
PG  - 1048-1052
LID - 10.1111/eci.12691 [doi]
AB  - BACKGROUND: Previous studies suggested that obesity could negatively affect the 
      response to antitumour necrosis factor-alpha (TNFalpha) agents in rheumatoid arthritis 
      (RA). However, data are lacking on whether obesity affects the response to 
      abatacept (ABA). We aimed to determine whether body mass index (BMI) affects the 
      response to ABA in RA. MATERIALS AND METHODS: In this multicenter retrospective 
      study, we included RA patients who received ABA. BMI was calculated at the 
      initiation of treatment. After 6 months of treatment, change from baseline in 
      DAS28, pain on a visual analog scale, erythrocyte sedimentation rate and 
      C-reactive protein level, tender and swollen joint count were analysed. The 
      primary endpoint was decrease in DAS28 >/= 1.2. Secondary outcomes were good 
      response and remission by EULAR criteria. RESULTS: At baseline, among 141 RA 
      patients included, the median [interquartile range] BMI was 26.0 [22.9-30.8] 
      kg/m(2). The number of patients with normal weight, overweight and obesity was 64 
      (45.4%), 38 (27%) and 39 (27.6%), respectively. Baseline characteristics did not 
      differ among the three BMI subgroups. Univariate analysis revealed no difference 
      in BMI between responders and nonresponders: DAS28 decrease >/= 1.2 (25.0 
      [23.4-31.3] vs. 26.3 [22.9-30.2], P = 0.95), EULAR good response (26.4 
      [23.5-30.9] vs. 26.0 [22.9-30.6], P = 0.96) and remission (26.7 [21.7-30.3] vs. 
      26.0 [23.0-30.1], P = 0.83). CONCLUSION: In our real-life study, BMI did not 
      affect the response to ABA in RA. If confirmed, these results suggest that 
      obesity is not a limitation of ABA use in RA.
CI  - (c) 2016 Stichting European Society for Clinical Investigation Journal Foundation.
FAU - Gardette, Anais
AU  - Gardette A
AD  - Sorbonne Paris Cite, Universite Paris Diderot, Paris, France.
AD  - Service de Rhumatologie, Assistance Publique - Hopitaux de Paris (APHP), Hopital 
      Bichat, Paris, France.
FAU - Ottaviani, Sebastien
AU  - Ottaviani S
AD  - Sorbonne Paris Cite, Universite Paris Diderot, Paris, France.
AD  - Service de Rhumatologie, Assistance Publique - Hopitaux de Paris (APHP), Hopital 
      Bichat, Paris, France.
FAU - Sellam, Jeremie
AU  - Sellam J
AD  - Universite Pierre et Marie Curie, Paris, France.
AD  - Service de Rhumatologie, DHU i2B and Inserm UMRS_938, APHP, Hopital 
      Saint-Antoine, Paris, France.
FAU - Berenbaum, Francis
AU  - Berenbaum F
AD  - Universite Pierre et Marie Curie, Paris, France.
AD  - Service de Rhumatologie, DHU i2B and Inserm UMRS_938, APHP, Hopital 
      Saint-Antoine, Paris, France.
FAU - Liote, Frederic
AU  - Liote F
AD  - UMR-S 1132, Inserm, Universite Paris Diderot, Paris, France.
AD  - Service de Rhumatologie, APHP, Hopital Lariboisiere, Paris, France.
FAU - Fautrel, Bruno
AU  - Fautrel B
AD  - Universite Pierre et Marie Curie, Paris, France.
AD  - Service de Rhumatologie, APHP, Hopital La Pitie Salpetriere, Paris, France.
FAU - Palazzo, Elisabeth
AU  - Palazzo E
AD  - Sorbonne Paris Cite, Universite Paris Diderot, Paris, France.
AD  - Service de Rhumatologie, Assistance Publique - Hopitaux de Paris (APHP), Hopital 
      Bichat, Paris, France.
FAU - Meyer, Alain
AU  - Meyer A
AD  - Service de Rhumatologie, Federation de Medecine Translationnelle, Centre de 
      Reference des Maladies Autoimmunes Rares, Hopitaux Universitaires de Strasbourg, 
      Strasbourg, France.
AD  - Service de Physiologie Exploration Fonctionnelle Musculaire, Federation de 
      Medecine Translationnelle, Hopitaux Universitaires de Strasbourg, Strasbourg, 
      France.
FAU - Sibilia, Jean
AU  - Sibilia J
AD  - Service de Rhumatologie, Federation de Medecine Translationnelle, Centre de 
      Reference des Maladies Autoimmunes Rares, Hopitaux Universitaires de Strasbourg, 
      Strasbourg, France.
FAU - Dieude, Philippe
AU  - Dieude P
AD  - Sorbonne Paris Cite, Universite Paris Diderot, Paris, France.
AD  - Service de Rhumatologie, Assistance Publique - Hopitaux de Paris (APHP), Hopital 
      Bichat, Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20161107
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Antirheumatic Agents)
RN  - 7D0YB67S97 (Abatacept)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Abatacept/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/epidemiology/metabolism
MH  - Blood Sedimentation
MH  - Body Mass Index
MH  - C-Reactive Protein/metabolism
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Obesity/*epidemiology
MH  - Overweight/epidemiology
MH  - Pain Measurement
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Abatacept
OT  - obesity
OT  - rheumatoid arthritis
EDAT- 2016/10/14 06:00
MHDA- 2017/05/04 06:00
CRDT- 2016/10/14 06:00
PHST- 2016/02/22 00:00 [received]
PHST- 2016/10/08 00:00 [accepted]
PHST- 2016/10/14 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
PHST- 2016/10/14 06:00 [entrez]
AID - 10.1111/eci.12691 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2016 Dec;46(12):1048-1052. doi: 10.1111/eci.12691. Epub 2016 
      Nov 7.